Point of Care Tests VerifyNow P2Y12 and INNOVANCE PFA P2Y Compared to Light Transmittance Aggregometry After Fibrinolysis

Overview

Journal Clin Appl Thromb Hemost

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2018 May 4

PMID 29719963

Citations 5

Authors

Vincent Roule

Pierre Ardouin

Yohan Repesse

Agnes Le Querrec

Katrien Blanchart

Adrien Lemaitre

Remi Sabatier

Annie Borel-Derlon

Farzin Beygui

Affiliations

Soon will be listed here.

Abstract

Detection of high on-treatment platelet reactivity (HPR) by point-of-care tests has not been validated after successful fibrinolysis for ST-elevation myocardial infarction. We assessed the validity of the point-of-care VerifyNow P2Y12 (VN) and INNOVANCE PFA P2Y (PFA) tests on HPR compared to light transmittance aggregometry (LTA) in these patients. The HPR was identified in 10 (34.5%) patients, 15 (51.7%) patients, and 14 (50%) patients using LTA, VN, and PFA, respectively. Discrepancies were observed between the tests despite significant correlations between platelet reactivity measures by LTA and VN ( r = 0.74; P < .0001) and LTA and PFA ( r = .75; P < .0001). Compared to LTA, VN and PFA were associated with a 92% and 53% and 92% and 64% positive predictive value (PPV) and negative predictive value (NPV), respectively, in detecting HPR. When combined, VN and PFA results yielded 90% and 100% PPV and NPV values if discrepancies between the 2 tests were considered as non-HPR. The VN or PFA identify patients without HPR correctly but overestimate the proportion of HPR patients. The association of the 2 tests, in case of HPR, improves the accuracy of the detection of HPR.

Citing Articles

Platelet microRNAs as Potential Novel Biomarkers for Antiplatelet Therapy with P2Y Inhibitors and Their Association with Platelet Function.

Gumiezna K, Bednarek A, Sygitowicz G, Maciejak-Jastrzebska A, Barus P, Hunia J J Clin Med. 2024; 13(1).

PMID: 38202070 PMC: 10780110. DOI: 10.3390/jcm13010063.

Cangrelor Dosing and Monitoring for Prevention of Acute Systemic-to-Pulmonary Artery Shunt Thrombosis in Neonates.

Anton-Martin P, Matherne E, Kramer J, Joseph N, Rayburn M J Pediatr Pharmacol Ther. 2022; 27(8):707-714.

PMID: 36415767 PMC: 9674352. DOI: 10.5863/1551-6776-27.8.707.

Platelet Activity and Cardiovascular Risk in CKD and Peripheral Artery Disease.

Cofer L, Soomro Q, Xia Y, Luttrell-Williams E, Myndzar K, Charytan D Kidney Int Rep. 2022; 7(10):2242-2250.

PMID: 36217517 PMC: 9546761. DOI: 10.1016/j.ekir.2022.07.169.

A Pharmacogenetic Study of in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy.

Angulo-Aguado M, Panche K, Tamayo-Agudelo C, Ruiz-Torres D, Sambracos-Parrado S, Nino-Orrego M J Pers Med. 2021; 11(5).

PMID: 34065778 PMC: 8150782. DOI: 10.3390/jpm11050400.

MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review.

Czajka P, Fitas A, Jakubik D, Eyileten C, Gasecka A, Wicik Z Front Physiol. 2021; 12:652579.

PMID: 33935804 PMC: 8081881. DOI: 10.3389/fphys.2021.652579.

References

Savcic M, Hauert J, Bachmann F, Wyld P, Geudelin B, Cariou R . Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999; 25 Suppl 2:15-9. View

Rasmanis G, Vesterqvist O, Green K, Edhag O, Henriksson P . Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction. Br Heart J. 1992; 68(4):374-6. PMC: 1025135. DOI: 10.1136/hrt.68.10.374. View

Eisenberg P, Sobel B, Jaffe A . Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1992; 19(5):1065-9. DOI: 10.1016/0735-1097(92)90296-y. View

Sabatine M, Cannon C, Gibson C, Lopez-Sendon J, Montalescot G, Theroux P . Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352(12):1179-89. DOI: 10.1056/NEJMoa050522. View

Gurbel P, Bliden K, Hayes K, Yoho J, Herzog W, Tantry U . The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005; 45(9):1392-6. DOI: 10.1016/j.jacc.2005.01.030. View

Chen Z, Jiang L, Chen Y, Xie J, Pan H, Peto R . Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366(9497):1607-21. DOI: 10.1016/S0140-6736(05)67660-X. View

van Werkum J, van der Stelt C, Seesing T, Hackeng C, Ten Berg J . A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost. 2006; 4(11):2516-8. DOI: 10.1111/j.1538-7836.2006.02187.x. View

ODonoghue M, Wiviott S . Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?. Circulation. 2006; 114(22):e600-6. DOI: 10.1161/CIRCULATIONAHA.106.643171. View

Geisler T, Kapp M, Gohring-Frischholz K, Daub K, Dosch C, Bigalke B . Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart. 2007; 94(6):743-7. DOI: 10.1136/hrt.2006.100891. View

10.

Paniccia R, Antonucci E, Gori A, Marcucci R, Giglioli C, Antoniucci D . Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost. 2007; 5(9):1839-47. DOI: 10.1111/j.1538-7836.2007.02656.x. View

11.

Heestermans A, van Werkum J, Taubert D, Seesing T, von Beckerath N, Hackeng C . Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 2008; 122(6):776-81. DOI: 10.1016/j.thromres.2008.01.021. View

12.

Gasparyan A, Watson T, Lip G . The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008; 51(19):1829-43. DOI: 10.1016/j.jacc.2007.11.080. View

13.

Varenhorst C, James S, Erlinge D, Braun O, Brandt J, Winters K . Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J. 2009; 157(3):562.e1-9. DOI: 10.1016/j.ahj.2008.11.021. View

14.

Cuisset T, Frere C, Quilici J, Morange P, Mouret J, Bali L . Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv. 2009; 1(6):649-53. DOI: 10.1016/j.jcin.2008.08.018. View

15.

Elsenberg E, van Werkum J, van de Wal R, Zomer A, Bouman H, Verheugt F . The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost. 2009; 102(4):719-27. DOI: 10.1160/TH09-05-0285. View

16.

Linnemann B, Schwonberg J, Rechner A, Mani H, Lindhoff-Last E . Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol. 2010; 89(6):597-605. DOI: 10.1007/s00277-009-0881-9. View

17.

Althoff T, Fischer M, Langer E, Ziemer S, Baumann G . Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. Thromb Res. 2010; 125(5):e190-6. DOI: 10.1016/j.thromres.2010.01.003. View

18.

Gasparyan A . Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vasc Health Risk Manag. 2010; 6:109-12. PMC: 2860443. DOI: 10.2147/vhrm.s9087. View

19.

Kim I, Jeong Y, Kang M, Koh J, Park Y, Hwang S . Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. J Thromb Thrombolysis. 2010; 30(4):486-95. DOI: 10.1007/s11239-010-0484-2. View

20.

Mehran R, Rao S, Bhatt D, Gibson C, Caixeta A, Eikelboom J . Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123(23):2736-47. DOI: 10.1161/CIRCULATIONAHA.110.009449. View